Amnioinfusion for Fetal Renal Failure
- Conditions
- Multicystic Dysplastic KidneyPolycystic Kidney DiseaseFetal Renal AnomalyAnhydramniosPotter SyndromeLung HypoplasiaMulticystic Renal Dysplasia, BilateralLower Urinary Tract Obstructive SyndromeBilateral Renal Agenesis
- Registration Number
- NCT06728228
- Lead Sponsor
- Fetal Care Center, PLLC
- Brief Summary
The goal of this clinical trial is to learn if serial amnioinfusions can improve the chances of survival for fetuses with severe kidney problems that cause low amniotic fluid (anhydramnios). Low amniotic fluid can affect lung development and may lead to serious health issues for the fetus. The main questions this study aims to answer are:
* Can serial amnioinfusion increase the chances of survival for these fetuses?
* Does this procedure improve chances of survival until dialysis and/or kidney transplant?
Participants will:
* Receive regular amnioinfusions, which is a procedure that adds fluid to the amniotic cavity.
* Undergo monitoring to check the effects on the fetus and mother.
This study will help researchers understand if amnioinfusion is a useful treatment for fetal kidney problems and may provide valuable information for similar cases in the future.
- Detailed Description
Fetal renal failure (FRF) is a severe and life-threatening condition caused by congenital abnormalities or inherited kidney diseases. In the womb, when the kidneys fail to function properly, this leads to a condition called anhydramnios-a complete lack of amniotic fluid. Amniotic fluid is essential for the fetus's lung development, particularly during the canalicular phase of pulmonary development, which occurs between 16 and 28 weeks of gestation. Without sufficient amniotic fluid, the lungs cannot develop properly, resulting in a condition known as pulmonary hypoplasia. Severe hypoplasia has previously been described as almost always fatal, typically leading to neonatal death shortly after birth.
In recent years, promising advances in fetal therapies have opened new doors for treating conditions that were once considered untreatable. One such intervention involves serial amnioinfusion, a procedure where sterile saline or another isotonic fluid is injected into the amniotic sac to restore fluid levels. Early studies, including the RAFT trial (Renal Anhydramnios Fetal Therapy), have demonstrated that this approach may improve survival rates by promoting lung development in fetuses with FRF. Building upon these findings, this study seeks to further evaluate the safety and effectiveness of serial amnioinfusion in improving neonatal outcomes for families facing this diagnosis.
This study will enroll approximately 60 pregnant individuals carrying singleton pregnancies complicated by FRF and anhydramnios. Participants will be divided into two groups: an intervention group, which will receive serial amnioinfusion procedures as deemed appropriate by the study doctor, and a control group, which will not undergo interventions and will receive comfort care for their pregnancies. The primary goals of the study are to evaluate maternal safety, assess fetal survival to dialysis, and determine survival to kidney transplant eligibility.
The amnioinfusion procedures will be performed at the Fetal Care Center by a team of experts in fetal procedures. To ensure patient safety, the study includes a rigorous monitoring plan to track any potential adverse events in real time. Data from imaging studies (e.g., ultrasound, echocardiogram, MRI) and laboratory biomarkers will be collected to evaluate fetal and maternal responses to the treatment. While the study focuses on improving outcomes for individual patients, it also has broader implications for science and society. By systematically analyzing the benefits and risks of serial amnioinfusion, this research could help refine treatment protocols and set the stage for new standards of care for FRF. For the families involved, participation in this study offers the possibility of improved survival for their children, with potential eligibility for life-saving kidney transplants in the future.
This study represents a critical step toward addressing a condition that has long been considered untreatable. Through collaboration, innovation, and rigorous research, the team aims to provide hope for families affected by FRF.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 35
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Fetal Survival to Dialysis Birth to either survival to >=14 days and placement of dialysis access, or nonsurvival, up to 3 weeks. Proportion of neonates surviving to \>= 14 days and placement of dialysis access after serial amnioinfusions (defined as use of a dialysis catheter for \>=14 continuous days)
Fetal Survival to Transplant >=2 years after delivery. The proportion of neonates who survive to receive a kidney transplant following continuous, successful dialysis.
Incidence of Maternal Treatment-Emergent Adverse Events [Safety and Tolerability] From enrollment in the study through delivery and up to 30 days postpartum. Maternal safety will be assessed by tracking adverse events, including bleeding, infections, and preterm rupture of membranes, at each visit, after procedures, and postpartum. These events will be documented at each prenatal visit, following every amnioinfusion, at delivery, and during a follow-up period of at least 30 days postpartum. The safety evaluation will focus on identifying procedure-related complications and ensuring the well-being of participants throughout the study.
- Secondary Outcome Measures
Name Time Method Number of infusions prior to rupture of membranes among participants in the intervention group During the pregnancy, up to 9 months The practicality of performing serial amnioinfusions for early pregnancy renal anhydramnios will be evaluated by counting the number of infusions administered before rupture of membranes in the intervention group.
Mean gestational age at rupture of membranes in the intervention group During the pregnancy, up to 9 months The feasibility of serial amnioinfusions will be assessed by determining the average gestational age at which rupture of membranes occurs in the intervention group.
Mean gestational age at delivery in the intervention group During the pregnancy, up to 9 months The feasibility of serial amnioinfusions will be measured by calculating the mean gestational age at delivery among participants in the intervention group.
Rate of fetal demise in utero among participants in the non-intervention group During the pregnancy, up to 9 months An exploratory analysis will examine the natural progression of untreated early pregnancy renal anhydramnios by analyzing the rate of in utero fetal demise in the non-intervention group.
Mean gestational age at delivery in the non-intervention group During the pregnancy, up to 9 months An exploratory study will investigate the natural history of untreated early pregnancy renal anhydramnios by calculating the average gestational age at delivery for participants in the non-intervention group.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Fetal Care Center
🇺🇸Dallas, Texas, United States
Fetal Care Center🇺🇸Dallas, Texas, United StatesKevin P Magee, M.D.Contact(972) 566-5600kevin.magee@fetalcaredallas.com